Table 2.
Functional characteristics of intracellular processes in CD4+ and CD8+ cells following PHA activation in ankylosing spondylitis patients before and during infliximab (IFX) therapy.
| Parameter | Healthy controls (n = 9) | Before IFX therapy (n = 13) | Week 2 after IFX therapy (n = 11) | Week 6 after IFX therapy (n = 8) | |
|---|---|---|---|---|---|
| Cytoplasmic Ca2+ | |||||
|
| |||||
| CD4+ | AUC (U) | 63.24 [58.00–107.9] | 82.43 [64.22–255.8] | 93.57 [56.89–201.0] | 96.21 [87.13–158.10] |
| Max (rpv) | 1.156 [1.132–1.256] | 1.268 [1.174–1.623] | 1.321 [1.149–1.477] | 1.254 [1.216–1.420] | |
| t max (s) | 258.4 [192.1–283.5] | 527.5 [327.9 595.3]* | 471.1 [288.2–594.3]* | 594.7 [290.5–595.5]* | |
| CD8+ | AUC (U) | 48.76 [38.53–93.22] | 88.52 [54.65–327.8] | 104.8 [42.14–180.8] | 81.55 [58.51–407.1] |
| Max (rpv) | 1.139 [1.089–1.262] | 1.247 [1.124–1.852] | 1.318 [1.120–1.434] | 1.220 [1.125–1.819] | |
| t max (s) | 228.6 [162.1–593.2] | 594.3 [294.6–595.6]* | 594.4 [422.9–596.1]* | 282.7 [232.9–531.0] | |
|
| |||||
| Mitochondrial Ca2+ | |||||
|
| |||||
| CD4+ | AUC (U) | 61.64 [37.97–94.43] | 66.00 [41.55–95.52] | 64.87 [42.90–105.4] | 67.60 [49.29–104.2] |
| Max (rpv) | 1.194 [1.121–1.272] | 1.207 [1.103–1.241] | 1.149 [1.114–1.281] | 1.172 [1.159–1.266] | |
| t max (s) | 594.0 [211.9–594.9] | 593.3 [384.7–595.3] | 595.2 [593.0–596.2] | 595.1 [386.6–596.4] | |
| CD8+ | AUC (U) | 106.9 [71.64–144.5] | 87.79 [62.47–101.4] | 71.31 [53.46–175.0] | 118.8 [67.55–249.9] |
| Max (rpv) | 1.250 [1.152–1.404] | 1.187 [1.130–1.217] | 1.154 [1.131–1.400] | 1.259 [1.143–1.539] | |
| t max (s) | 144.2 [121.6–160.6] | 577.1 [167.8–594.2]* | 468.8 [165.3–594.7]* | 198.7 [169.8–248.4] | |
|
| |||||
| Nitric oxide production | |||||
|
| |||||
| CD4+ | AUC (U) | 3.318 [−8.315–18.84] | 47.76 [1.727–97.18]* | 22.20 [−8.903–37.95] | −3.055 [−13.24–9.005]# |
| Max (rpv) | 1.013 [1.000–1.043] | 1.113 [1.011–1.282]* | 1.046 [1.000–1.081] | 1.001 [1.000–1.034]# | |
| t max (s) | 198.7 [34.55–321.8] | 594.3 [228.2–594.8]* | 331.2 [0.000–556.5] | 107.9 [0.000–252.5]# | |
| CD8+ | AUC (U) | −9.481 [−19.97–24.30] | 41.31 [6.068–109.8]* | 9.641 [−11.20–29.92] | −11.80 [−29.93–4.094]# |
| Max (rpv) | 1.003 [1.000–1.051] | 1.099 [1.011–1.330]* | 1.025 [1.001–1.078] | 1.000 [1.000–1.001]# | |
| t max (s) | 51.08 [0.000–185.2] | 594.2 [185.2–594.8]* | 289.1 [54.03–553.5] | 0.001 [0.000–130.5]# | |
|
| |||||
| Superoxide generation | |||||
|
| |||||
| CD4+ | AUC (U) | 79.27 [64.68–88.90] | 75.65 [70.70–92.61] | 82.64 [58.40–96.68] | 70.99 [56.09–83.99] |
| CD8+ | AUC (U) | 73.15 [62.21–80.33] | 74.97 [61.28–98.75] | 83.87 [58.13–90.74] | 60.34 [51.38–85.42] |
Data are expressed as median [interquartile range] *versus control P < 0.05; #versus before IFX therapy P < 0.05; AUC: area under the curve, Max: maximum value, t max : time to reach maximum.